View Post

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Gina Mauro From: onclive.com Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented during the virtual 2020 San Antonio Breast Cancer Symposium.1,2 At the 9-mg and 18-mg doses of enobosarm, the 6-month clinical benefit rate (CBR) …

View Post

New drugs show rare promise against advanced breast cancer

In Clinical Trials by Barbara Jacoby

By: MARILYNN MARCHIONE AP Chief Medical Writer From: effinghamdailynews.com Doctors reported unusually good results from tests of two experimental drugs in women with an aggressive form of breast cancer that had spread widely and resisted many previous treatments. One drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat. The other pairs a sort …

View Post

Immunotherapy Continues to Show Promise in TNBC

In In The News by Barbara Jacoby

By: Jessica Hergert From: onclive.com Nearly 1 year following the first checkpoint inhibitor approval in advanced triple-negative breast cancer, additional immunotherapeutic agents are poised to enter the field, according to Rita Nanda, MD. “Historically, breast cancer was not believed to be an immunogenically active tumor [type],” said Nanda. “We have seen some emerging—likely practice-changing—data that may lead to approvals of …

View Post

Potential Immunotherapy Response Markers Emerge in Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Ellie Leick From: onclive.com Data suggest that baseline T-cell clonality and exhaustion markers have significant translational relevance and can serve as prognostic factors of response to pembrolizumab (Keytruda) as maintenance therapy in metastatic breast cancer, explained James M. Reuben, PhD, MBA. In a phase II trial that was presented at the 2019 San Antonio Breast Cancer Symposium, patients with …

View Post

Homing in on Targeted Treatment Strategies in Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour From: onclive.com The fields of early-stage hormone receptor (HR)–positive and metastatic HER2-positive breast cancer have made great strides in recent years, said Neelima Denduluri, MD, and such progress could be attributed to the emergence of tailored treatment strategies and the use of HER2-directed agents, respectively. “We’re making great headway in [the treatment of patients with] breast cancer. …

View Post

Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

In Clinical Trials by Barbara Jacoby

Insights From: William J. Gradishar, MD, Northwestern University; Sara A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center; Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute From: onclive.com Transcript:  Ian E. Krop, MD, PhD: At the San Antonio Breast Cancer Symposium in 2019 we saw the results of the ATEMPT trial. This was a trial that built on a previous study, …

View Post

Immunotherapeutic Agents Expand Treatment Landscape for Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Danielle Ternyila From: targetedonc.com Patients with advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC) can now be treated with the FDA-approved combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) in the frontline setting, based on data from the phase III IMpassion130 trial (NCT02425891). According to Elizabeth Mittendorf, MD, PhD, this is a monumental improvement for the treatment of patients with …

View Post

Patients with Breast Cancer Who Face Treatment Disparities Grow Their Role at Major Medical Conference

In In The News by Barbara Jacoby

By: Maimah Karmo From: curetoday.com Women of color with breast cancer tend to experience higher rates of death compared with Caucasian women who have the disease, and this in part due to women of color not having a meaningful presence in clinical trials or at major conferences where clinical data is presented, according to Maimah Karmo. Karmo is a breast …

View Post

Patient-Driven Solutions May Lead to Greater Metastatic Breast Cancer Clinical Trial Participation

In Clinical Trials by Barbara Jacoby

By: John Schieszer From: oncologynurseadvisor.com Findings from a patient-led study suggest that adopting a collaborative, systematic, solutions-based approach may enable more patients with metastatic breast cancer (MBC) to participate in clinical trials. The rate of participation in clinical trials for breast cancer is dismally low, which is slowing drug development and adding to overall costs. However, more patients living with …

View Post

Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: apnews.com Seattle Genetics, Inc. (Nasdaq:SGEN) today announced it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tucatinib. This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients …